Source comparison
Thymosin Alpha-1 Dosage for Autoimmune Support: Protocol Comparison
Maintenance / Prevention 1.6mg 2x weekly 3.2mg Treg frequency >5% of CD4+ cells Ongoing Baseline effective dose for stable autoimmune models Moderate Activity 3x weekly 9.6mg CRP <3mg/L, reduced autoantibody titres 8–12 weeks Standard escalation for active inf
This comparison does not assign a generated winner or score.
- Maintenance / Prevention
- 1.6mg
- 2x weekly
- 3.2mg
- Treg frequency >5% of CD4+ cells
- Ongoing
- Baseline effective dose for stable autoimmune models
- Moderate Activity
- 3x weekly
- 9.6mg
- CRP <3mg/L, reduced autoantibody titres
- 8–12 weeks
- Standard escalation for active inflammation without organ involvement
- Severe Flare
- 4.8–6.4mg
- 14.4–19.2mg
- Normalised cytokine panel, Th17 suppression
- 4–6 weeks, then taper
- Short-term high-dose intervention combined with standard immunosuppression
- Combination Protocols
- 6.4mg
- Synergistic immune modulation with low-dose biologics
- Variable
- Used alongside methotrexate, azathioprine, or low-dose IL-2 therapy